Artal Group’s Rubius Therapeutics, Inc RUBY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-2,042,666
| Closed | -$44K | – | 140 |
|
|
2023
Q1 | $44K | Hold |
2,042,666
| – | – | ﹤0.01% | 117 |
|
|
2022
Q4 | $357K | Hold |
2,042,666
| – | – | 0.02% | 118 |
|
|
2022
Q3 | $886K | Sell |
2,042,666
-1,658,914
| -45% | -$1.24M | 0.04% | 119 |
|
|
2022
Q2 | $3.15M | Hold |
3,701,580
| – | – | 0.17% | 80 |
|
|
2022
Q1 | $20.4M | Hold |
3,701,580
| – | – | 0.85% | 27 |
|
|
2021
Q4 | $35.8M | Sell |
3,701,580
-454,045
| -11% | -$6.3M | 0.97% | 28 |
|
|
2021
Q3 | $74.3M | Sell |
4,155,625
-478,166
| -10% | -$10.4M | 1.66% | 14 |
|
|
2021
Q2 | $113M | Sell |
4,633,791
-250,000
| -5% | -$6.25M | 2.3% | 12 |
|
|
2021
Q1 | $129M | Buy |
4,883,791
+1,104,878
| +29% | +$16.1M | 2.29% | 8 |
|
|
2020
Q4 | $28.7M | Hold |
3,778,913
| – | – | 0.62% | 42 |
|
|
2020
Q3 | $18.9M | Sell |
3,778,913
-73,428
| -2% | -$389K | 0.46% | 47 |
|
|
2020
Q2 | $23M | Sell |
3,852,341
-31,450
| -0.8% | -$186K | 0.64% | 39 |
|
|
2020
Q1 | $17.3M | Buy |
3,883,791
+1,050,000
| +37% | +$7.8M | 0.73% | 32 |
|
|
2019
Q4 | $26.9M | Hold |
2,833,791
| – | – | 1.04% | 21 |
|
|
2019
Q3 | $22.2M | Hold |
2,833,791
| – | – | 0.89% | 19 |
|
|
2019
Q2 | $44.6M | Sell |
2,833,791
-75,000
| -3% | -$1.21M | 1.8% | 12 |
|
|
2019
Q1 | $52.6M | Hold |
2,908,791
| – | – | 2.15% | 11 |
|
|
2018
Q4 | $46.8M | Hold |
2,908,791
| – | – | 1.73% | 12 |
|
|
2018
Q3 | $69.8M | Buy |
+2,908,791
| New | +$66.5M | 1.82% | 9 |
|
Artal Group's RUBY Position: Q2 2023 in Review
Artal Group sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2023, closing a stake of 2,042,666 shares — an estimated $44K sold.
Artal Group first reported a position in RUBY in Q3 2018 and held it in 19 quarters. The position peaked at $129M in Q1 2021. 0 funds tracked by Wall St. Rank hold RUBY as of Q2 2023.
- Artal Group reported no remaining Rubius Therapeutics, Inc position as of Q2 2023 after selling out during the quarter.
- Artal Group sold 2,042,666 Rubius Therapeutics, Inc shares in Q2 2023, an estimated $44K.
- Artal Group first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 19 quarters.
- Artal Group's Rubius Therapeutics, Inc position peaked at $129M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2023.
Based on Artal Group's 13F filing for Q2 2023, filed 11 Aug 2023.